Government-Owned Inventions; Availability for Licensing, 67738-67740 [E7-23193]
Download as PDF
<![CDATA[
67738
Federal Register / Vol. 72, No. 230 / Friday, November 30, 2007 / Notices
TABLE 1.—ANNUALIZED ESTIMATE OF HOUR BURDEN
Number of
respondents
Type of respondents
Frequency of
response
Average time
for response
(hr)
Total hour
burden *
GRIP Awardees ...............................................................................................
101
1
0.50
50.5
Total ..........................................................................................................
101
1
0.50
50.5
* Total Burden = N Respondents × Response Frequency × minutes to complete/60.
TABLE 2.—ANNUALIZED COST TO RESPONDENTS
Number of
respondents
Type of respondents
Frequency of
response
Approximate
hourly wage
rate/hr
Total
respondent
cost *
GRIP Awardees ...............................................................................................
101
1
$13
656.50
Total ..........................................................................................................
101
1
13
656.50
* Total Respondent Cost = N Respondents × Response Frequency × minutes to complete/60 × hourly rate.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Dr. Linda Kupfer,
Fogarty International Center, National
Institutes of Health, 16 Center Drive,
Bethesda, MD 20892, or call non-tollfree number 301–496–3288, or e-mail
your request, including your address to:
kupferl@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
rwilkins on PROD1PC63 with NOTICES
FOR FURTHER INFORMATION CONTACT:
Dated: November 20, 2007.
Timothy Tosten,
Executive Officer, FIC, National Institutes of
Health.
[FR Doc. E7–23235 Filed 11–29–07; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
16:27 Nov 29, 2007
Jkt 214001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
A Family of Small Molecules for
Selective Inhibition of Wip1
Phosphatase
Description of Technology: The Wip1
phosphatase acts on proteins containing
a particular phosphorylated amino acid
sequence. Studies have shown that
Wip1 is overexpressed in a number of
human cancers, including breast cancer,
neuroblastoma and ovarian cancer.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Wip1 activity has also been shown to
have a suppressive effect on the tumor
suppressor p53. This suggested that
inhibition of Wip1 could be of
therapeutic value in the treatment of
cancer.
NIH inventors have developed small
molecules that simulate the structure of
the amino acid sequence that Wip1
recognizes. The structure of the small
molecules allows for specific targeting
to Wip1. These small molecules have
the ability to significantly inhibit Wip1
phosphatase activity at the micromolar
level. As a result, these small molecules
can be used in the design of
therapeutics for cancers that
overexpress Wip1.
Applications: Treatment of cancer,
including but not limited to breast
cancer, ovarian cancer and
neuroblastoma.
Can be used either alone or in
combination with other known anticancer therapeutics.
Advantages: Structure of the inhibitor
allows targeting of Wip1 without
inhibition of related phosphatases and
their biological processes, possibly
leading to fewer undesired effects
during treatment.
Small molecules are stable and have
the ability to effectively penetrate cells.
Can be applied to many different
types of cancer.
Benefits: The current lack of Wip1
inhibitors means that development of
the small molecules could lead to the
occupation of a significant position in
the cancer therapeutic market.
The successful inhibition of a new
target in cancer therapy could provide
far-reaching social benefit in the
treatment of multiple cancers.
Inventors: Ettore Appella et al. (NCI).
E:\FR\FM\30NON1.SGM
30NON1
Federal Register / Vol. 72, No. 230 / Friday, November 30, 2007 / Notices
rwilkins on PROD1PC63 with NOTICES
U.S. Patent Status: U.S. Patent
Application No. 60/969,258 (HHS
Reference No. E–302–2007/0–US–01).
Licensing Contact: David A.
Lambertson, Ph.D.; Phone: (301) 435–
4632; Fax: (301) 042–0220; E-mail:
lambertsond@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute’s
Laboratory of Cell Biology is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize therapeutics for cancers
that overexpress Wip1. Please contact
John D. Hewes, Ph.D. at 301–435–3121
or hewesj@mail.nih.gov for more
information.
Selenocysteine Mediated Hybrid
Antibody Molecules
Description of Technology: Available
for licensing is a new class of hybrid
molecules composed of an antibody, or
antibody fragment, and a small
synthetic molecule (such as a small
molecule inhibitor, or cytotoxic
compound). These biological and
chemical components are covalently
linked at an engineered selenocysteine
near the C-terminus of the antibody, or
antibody fragment. Through this
covalent linkage, the chemical and the
biological component can acquire
properties of one another. For example,
the synthetic molecule acquires
antibody properties such as circulatory
half-life, effector functions, and ability
to interfere with protein interactions
whereas the antibody, or antibody
fragment, acquires properties of the
small synthetic molecule such as
specificity, affinity, and stability to bind
to targets that are sterically inaccessible
to immunoglobulins. The technology
can also be used to equip an antibody,
or antibody fragment, with a small
synthetic molecule that enhances target
destruction or imaging capabilities
through site-selective biotinylation,
PEGylation, addition of an imaging
agent, or addition of a cytotoxic agent
such as a chemotherapeutic drug or a
chelate for radioisotope labeling. The
hybrid antibody molecules can be
engineered with a variety of small
synthetic molecules, and the
combination of immunogenic properties
and those of the small synthetic
molecules results in compounds with
powerful target destruction or imaging
capabilities. This technology could be
applied towards the targeted delivery of
small synthetic molecules to various
cell surface receptors, and may have
applicability as a prevention, diagnosis,
or therapy for numerous disease states.
Applications: Potent novel
compositions that retain immunogenic
VerDate Aug<31>2005
16:27 Nov 29, 2007
Jkt 214001
properties and those of small synthetic
molecules that can be produced at a
large scale; Method to prevent,
diagnose, and treat cancer, infectious
diseases and autoimmune diseases.
Market: Monoclonal antibody market
is projected to exceed $30 billion by
2010; Revenue from antibodies for
therapeutics and diagnostic uses are
expected to grow at an average annual
growth rate of 11.5%.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Christoph Rader et al.
(NCI).
Patent Status: U.S. Provisional
Application No. 60/909,665 filed 02 Apr
2007 (HHS Reference No. E–146–2007/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Center for
Cancer Research, Experimental
Transplantation and Immunology
Branch, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize Selenocysteine Mediated
Hybrid Antibody Molecules. Please
contact Dr. Christoph Rader at (301)
451–2235 or raderc@mail.nih.gov for
more information.
SLCO1B3 Genotyping to Predict a
Survival Prognosis of Prostate Cancer
Description of Technology: Steroid
hormones have been implicated in
playing a fundamental role in the
pathogenesis of prostate cancer.
Polymorphisms in the genes that code
for enzymes or hormones involved in
androgen regulatory pathway are
proposed to influence an individual’s
risk for developing prostate cancer.
Since many membrane transporters are
modulators of steroid hormones
absorption and tissue distribution,
genetic polymorphisms in genes
encoding these transporters may
account for the risk of prostate cancer
and the predicting of survival. The
OATP1B3 (formerly OATP8) steroid
uptake transporter is overexpressed in
prostate cancer, and polymorphisms in
SLCO1B3 have been associated with
altered testosterone uptake, and also an
increased prostate cancer risk.
This invention identifies two
polymorphic genetic markers in the
SLCO1B3 (formerly SLC21A8) gene,
called 334T>G and 699G>A, that can be
measured in genomic DNA obtained
from a blood sample to predict survival
from diagnosis of prostate cancer in that
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
67739
individual patient. This genetic
profiling result has profound clinical
applications in diagnosis for each
individual patient and ultimate
treatment regimen. Specifically, the
inventors have provided a correlation
between clinical outcome of SLCO1B3
genotype with median survival of
androgen independent prostate cancer.
They have also shown that the genotype
is predictive of testosterone uptake
through the OATP1B3 transporter, and
this information is useful to inform
clinical decisions regarding
antiandrogen therapy.
Advantages and Applications:
SLCO1B3 genotyping can be used in
combination on a gene chip with several
polymorphisms known to predict
survival of prostate cancer patients.
Thus the OATP1B3 polymorphism
would be one genetic marker in a series
of other markers that would be used to
inform clinical decisions.
SLCO1B3 upregulation can be used as
a prognostic tool.
Development Status: Initial
experiments have been performed with
clinical samples from patients with
prostate cancer.
Inventors: William D. Figg et al. (NCI).
Patent Status: U.S. Provisional
Application No. 60/879,503 filed 08 Jan
2007 (HHS Reference No. E–083–2007/
0–US–01).
Licensing Status: Available for
exclusive and non-exclusive licensing.
Licensing Contact: Mojdeh Bahar, J.D.;
301/435–2950; baharm@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute’s Medical
Oncology Branch is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the use of the SLCO1B3
genotyping to inform clinical decisions
regarding drug treatment, or prognosis
of prostate cancer. Please contact John
D. Hewes, Ph.D. at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
A New Method for Determining Level of
Immunosuppression in Humans
Description of Technology: These
inventions describe a method of
determining the level of
immunosuppression in a human subject
by determining the level of expression
of at least one selected T-Cell Receptor
subunit protein, or protein in the T
lymphocyte signal transduction
pathway, and comparing the level to
that found in healthy individuals.
Applications: The method can be
used to identify candidates for
autologous adoptive immunotherapy
E:\FR\FM\30NON1.SGM
30NON1
67740
Federal Register / Vol. 72, No. 230 / Friday, November 30, 2007 / Notices
and for identification of agents which
cause or reverse immunosuppression.
Development Status: Pre-clinical
stage.
Inventors: Augusto C. Ochoa et al.
(NCI).
Patent Status: U.S. Patent No.
5,583,002 issued 10 Dec 1996 (HHS
Reference No. E–231–1995/1–US–01);
U.S. Patent No. 5,556,763 issued 17
Sep 1996 (HHS Reference No. E–231–
1995/3–US–01);
U.S. Patent No. 5,889,143 issued 10
Dec 1996 (HHS Reference No. E–231–
1995/3–US–02);
U.S. Patent Application No. 09/
280,655 filed 29 Mar 1999 (HHS
Reference No. E–231–1995/3–US–03);
U.S. Patent No. 5,658,744 issued 19
Aug 1997 (HHS Reference No. E–232–
1995/0–US–01);
U.S. Patent No. 5,965,366 issued 12
Dec 1999 (HHS Reference No. E–232–
1995/1–US–01); and any foreign
equivalent patents and patent
applications.
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: John Stansberry;
301/435–5236; stansbej@mail.nih.gov.
Dated: November 14, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–23193 Filed 11–29–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
rwilkins on PROD1PC63 with NOTICES
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the United States in
accordance with 35 U.S.C. 207 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
VerDate Aug<31>2005
16:27 Nov 29, 2007
Jkt 214001
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Monoclonal Antibody to a Specific
Peptide–MHC Class II Complex
Description of Invention: T
lymphocytes play an important role in
the immune system by recognizing
foreign protein motifs on cells. T
lymphocytes are stimulated to recognize
these motifs through their interactions
with peptide-MHC complexes (pMHC).
Thus, studying pMHC is an important
aspect of understanding how the
immune system works, particularly with
regard to the development of vaccines.
Unfortunately, the detection of pMHC is
largely dependent on indirect assays,
due to the difficulty of producing
antibodies for specific pMHC.
This invention regards the
development of hybridomas (C4H3) for
the production of antibodies that are
highly specific for a particular pMHC
complex consisting of hen egg lysozyme
peptide 46-61 (HEL) and the I-Ak MHC
class II molecule. These antibodies can
be used for a myriad of purposes which
include studying how cells form pMHC.
Applications: Discovery of methods
for antigen delivery in the development
of vaccines.
Quantitation and distribution of
pMHC complexes on cells.
Study antigen processing in
experimental immunological research
systems.
Advantages: High specificity for the
pMHC complex of HEL-I-Ak MHC class
II molecule.
HEL-I-Ak is widely used in
experimental immunological research
systems, giving the hybridoma and
antibodies great applicability.
Inventors: Ronald N. Germain et al.
(NIAID).
Publications: 1. G Zhong et al.
Production, specificity, and
functionality of monoclonal antibodies
to specific peptide-major
histocompatibility complex class II
complexes formed by processing of
exogenous protein. Proc Natl Acad Sci
U S A. 1997 Dec 9; 94(25):13856–13861.
2. A Porgador et al. Localization,
quantitation, and in situ detection of
specific peptide-MHC class I complexes
using a monoclonal antibody.
Immunity. 1997 Jun; 6(6):715–726.
Patent Status: HHS Reference No. E–
021–2008/0–Research Tool. Patent
protection is not being pursued for this
technology.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Licensing Contact: David A.
Lambertson, Ph.D.; 301–435–4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity:
The NIAID Lymphocyte Biology
Section, Laboratory of Immunology is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
monoclonal antibody C4H3, specific for
HEL (46-61) bound to the MHC class II
molecule I-Ak. Please contact Ronald N.
Germain, M.D., Ph.D., at
rgermain@nih.gov for more information.
Bifunctional Compounds that Bind to
Hormone Receptors
Description of Technology: The
development and progression of
prostate cancer is dependent on the
androgen receptor (AR), a liganddependent transcription factor. In the
inactive form AR resides in the cytosolic
region of the cell and when activated,
AR is imported into the nucleus. Initial
hormonal therapy for prostate cancer
involves lowering serum levels of
testosterone to shut down AR activity.
Despite initial patient responses to
testosterone-depleting therapies,
prostate cancer becomes refractory to
hormonal therapy. Notably, AR is
reactivated in hormone-refractory
prostate cancer and reinstates its
proliferative and survival activity.
Available for licensing is a novel
chemical compound which is
bifunctional and binds to AR. This
compound is comprised of tubulinbinding and steroid receptor-binding
moieties. This compound is designed to
antagonize AR function in a
nonclassical manner by several
mechanisms and kills hormonerefractory prostate cells better than both
functional moieties. This compound is a
first-in-class of bifunctional steroid
receptor binding agents that can
antagonize steroid receptors in a variety
of hormone-dependent diseases, such as
breast and prostate cancer.
Applications: Therapeutic
compounds that selectively target
steroid receptor-expressing cancer cells
resulting in decreased toxicity.
Method to treat hormone resistant
prostate cancer and potentially other
steroid receptor dependent diseases
such as breast cancer.
Market: Prostate cancer is the second
most common type of cancer among
men, wherein one in six men will be
diagnosed with prostate cancer.
An estimated 218,890 new cases of
prostate cancer and 27,050 deaths due
to prostate cancer in the United States
in 2007.
E:\FR\FM\30NON1.SGM
30NON1
]]>Agencies
[Federal Register Volume 72, Number 230 (Friday, November 30, 2007)]
[Notices]
[Pages 67738-67740]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-23193]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
A Family of Small Molecules for Selective Inhibition of Wip1
Phosphatase
Description of Technology: The Wip1 phosphatase acts on proteins
containing a particular phosphorylated amino acid sequence. Studies
have shown that Wip1 is overexpressed in a number of human cancers,
including breast cancer, neuroblastoma and ovarian cancer. Wip1
activity has also been shown to have a suppressive effect on the tumor
suppressor p53. This suggested that inhibition of Wip1 could be of
therapeutic value in the treatment of cancer.
NIH inventors have developed small molecules that simulate the
structure of the amino acid sequence that Wip1 recognizes. The
structure of the small molecules allows for specific targeting to Wip1.
These small molecules have the ability to significantly inhibit Wip1
phosphatase activity at the micromolar level. As a result, these small
molecules can be used in the design of therapeutics for cancers that
overexpress Wip1.
Applications: Treatment of cancer, including but not limited to
breast cancer, ovarian cancer and neuroblastoma.
Can be used either alone or in combination with other known anti-
cancer therapeutics.
Advantages: Structure of the inhibitor allows targeting of Wip1
without inhibition of related phosphatases and their biological
processes, possibly leading to fewer undesired effects during
treatment.
Small molecules are stable and have the ability to effectively
penetrate cells.
Can be applied to many different types of cancer.
Benefits: The current lack of Wip1 inhibitors means that
development of the small molecules could lead to the occupation of a
significant position in the cancer therapeutic market.
The successful inhibition of a new target in cancer therapy could
provide far-reaching social benefit in the treatment of multiple
cancers.
Inventors: Ettore Appella et al. (NCI).
[[Page 67739]]
U.S. Patent Status: U.S. Patent Application No. 60/969,258 (HHS
Reference No. E-302-2007/0-US-01).
Licensing Contact: David A. Lambertson, Ph.D.; Phone: (301) 435-
4632; Fax: (301) 042-0220; E-mail: lambertsond@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute's
Laboratory of Cell Biology is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize therapeutics for cancers that
overexpress Wip1. Please contact John D. Hewes, Ph.D. at 301-435-3121
or hewesj@mail.nih.gov for more information.
Selenocysteine Mediated Hybrid Antibody Molecules
Description of Technology: Available for licensing is a new class
of hybrid molecules composed of an antibody, or antibody fragment, and
a small synthetic molecule (such as a small molecule inhibitor, or
cytotoxic compound). These biological and chemical components are
covalently linked at an engineered selenocysteine near the C-terminus
of the antibody, or antibody fragment. Through this covalent linkage,
the chemical and the biological component can acquire properties of one
another. For example, the synthetic molecule acquires antibody
properties such as circulatory half-life, effector functions, and
ability to interfere with protein interactions whereas the antibody, or
antibody fragment, acquires properties of the small synthetic molecule
such as specificity, affinity, and stability to bind to targets that
are sterically inaccessible to immunoglobulins. The technology can also
be used to equip an antibody, or antibody fragment, with a small
synthetic molecule that enhances target destruction or imaging
capabilities through site-selective biotinylation, PEGylation, addition
of an imaging agent, or addition of a cytotoxic agent such as a
chemotherapeutic drug or a chelate for radioisotope labeling. The
hybrid antibody molecules can be engineered with a variety of small
synthetic molecules, and the combination of immunogenic properties and
those of the small synthetic molecules results in compounds with
powerful target destruction or imaging capabilities. This technology
could be applied towards the targeted delivery of small synthetic
molecules to various cell surface receptors, and may have applicability
as a prevention, diagnosis, or therapy for numerous disease states.
Applications: Potent novel compositions that retain immunogenic
properties and those of small synthetic molecules that can be produced
at a large scale; Method to prevent, diagnose, and treat cancer,
infectious diseases and autoimmune diseases.
Market: Monoclonal antibody market is projected to exceed $30
billion by 2010; Revenue from antibodies for therapeutics and
diagnostic uses are expected to grow at an average annual growth rate
of 11.5%.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Christoph Rader et al. (NCI).
Patent Status: U.S. Provisional Application No. 60/909,665 filed 02
Apr 2007 (HHS Reference No. E-146-2007/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301/435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Center for Cancer Research, Experimental Transplantation and Immunology
Branch, is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize Selenocysteine Mediated Hybrid Antibody Molecules. Please
contact Dr. Christoph Rader at (301) 451-2235 or raderc@mail.nih.gov
for more information.
SLCO1B3 Genotyping to Predict a Survival Prognosis of Prostate Cancer
Description of Technology: Steroid hormones have been implicated in
playing a fundamental role in the pathogenesis of prostate cancer.
Polymorphisms in the genes that code for enzymes or hormones involved
in androgen regulatory pathway are proposed to influence an
individual's risk for developing prostate cancer. Since many membrane
transporters are modulators of steroid hormones absorption and tissue
distribution, genetic polymorphisms in genes encoding these
transporters may account for the risk of prostate cancer and the
predicting of survival. The OATP1B3 (formerly OATP8) steroid uptake
transporter is overexpressed in prostate cancer, and polymorphisms in
SLCO1B3 have been associated with altered testosterone uptake, and also
an increased prostate cancer risk.
This invention identifies two polymorphic genetic markers in the
SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be
measured in genomic DNA obtained from a blood sample to predict
survival from diagnosis of prostate cancer in that individual patient.
This genetic profiling result has profound clinical applications in
diagnosis for each individual patient and ultimate treatment regimen.
Specifically, the inventors have provided a correlation between
clinical outcome of SLCO1B3 genotype with median survival of androgen
independent prostate cancer. They have also shown that the genotype is
predictive of testosterone uptake through the OATP1B3 transporter, and
this information is useful to inform clinical decisions regarding
antiandrogen therapy.
Advantages and Applications: SLCO1B3 genotyping can be used in
combination on a gene chip with several polymorphisms known to predict
survival of prostate cancer patients. Thus the OATP1B3 polymorphism
would be one genetic marker in a series of other markers that would be
used to inform clinical decisions.
SLCO1B3 upregulation can be used as a prognostic tool.
Development Status: Initial experiments have been performed with
clinical samples from patients with prostate cancer.
Inventors: William D. Figg et al. (NCI).
Patent Status: U.S. Provisional Application No. 60/879,503 filed 08
Jan 2007 (HHS Reference No. E-083-2007/0-US-01).
Licensing Status: Available for exclusive and non-exclusive
licensing.
Licensing Contact: Mojdeh Bahar, J.D.; 301/435-2950;
baharm@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute's
Medical Oncology Branch is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize the use of the SLCO1B3 genotyping to inform
clinical decisions regarding drug treatment, or prognosis of prostate
cancer. Please contact John D. Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
A New Method for Determining Level of Immunosuppression in Humans
Description of Technology: These inventions describe a method of
determining the level of immunosuppression in a human subject by
determining the level of expression of at least one selected T-Cell
Receptor subunit protein, or protein in the T lymphocyte signal
transduction pathway, and comparing the level to that found in healthy
individuals.
Applications: The method can be used to identify candidates for
autologous adoptive immunotherapy
[[Page 67740]]
and for identification of agents which cause or reverse
immunosuppression.
Development Status: Pre-clinical stage.
Inventors: Augusto C. Ochoa et al. (NCI).
Patent Status: U.S. Patent No. 5,583,002 issued 10 Dec 1996 (HHS
Reference No. E-231-1995/1-US-01);
U.S. Patent No. 5,556,763 issued 17 Sep 1996 (HHS Reference No. E-
231-1995/3-US-01);
U.S. Patent No. 5,889,143 issued 10 Dec 1996 (HHS Reference No. E-
231-1995/3-US-02);
U.S. Patent Application No. 09/280,655 filed 29 Mar 1999 (HHS
Reference No. E-231-1995/3-US-03);
U.S. Patent No. 5,658,744 issued 19 Aug 1997 (HHS Reference No. E-
232-1995/0-US-01);
U.S. Patent No. 5,965,366 issued 12 Dec 1999 (HHS Reference No. E-
232-1995/1-US-01); and any foreign equivalent patents and patent
applications.
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: John Stansberry; 301/435-5236;
stansbej@mail.nih.gov.
Dated: November 14, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-23193 Filed 11-29-07; 8:45 am]
BILLING CODE 4140-01-P
